Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Workman

Showing results (251-260 of 268) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancerL R Kelland, V Smith, M Valenti, et al.
Laboratory Animals|July 1, 1988
UKCCCR guidelines for the welfare of animals in experimental neoplasiaP Workman, A Balmain, J A Hickman, et al.
Oncogene|August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
British Journal of Cancer|September 1, 1993
A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancerE G de Vries, J A Gietema, P Workman, et al.
British Journal of Cancer|October 27, 2005
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026B P Nutley, N F Smith, A Hayes, et al.
British Journal of Cancer|October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsA O'Donnell, A Padhani, C Hayes, et al.
British Journal of Cancer|August 15, 2013
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRIM Beloueche-Babari, Y Jamin, V Arunan, et al.
British Journal of Cancer|October 2, 2003
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotopeD R Collingridge, M Glaser, S Osman, et al.
British Journal of Cancer|December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysC Benson, J White, J De Bono, et al.
Pageof 27

Showing results (251-260 of 268) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancerL R Kelland, V Smith, M Valenti, et al.
Laboratory Animals|July 1, 1988
UKCCCR guidelines for the welfare of animals in experimental neoplasiaP Workman, A Balmain, J A Hickman, et al.
Oncogene|August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
British Journal of Cancer|September 1, 1993
A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancerE G de Vries, J A Gietema, P Workman, et al.
British Journal of Cancer|October 27, 2005
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026B P Nutley, N F Smith, A Hayes, et al.
British Journal of Cancer|October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsA O'Donnell, A Padhani, C Hayes, et al.
British Journal of Cancer|August 15, 2013
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRIM Beloueche-Babari, Y Jamin, V Arunan, et al.
British Journal of Cancer|October 2, 2003
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotopeD R Collingridge, M Glaser, S Osman, et al.
British Journal of Cancer|December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysC Benson, J White, J De Bono, et al.
Pageof 27